For the millions living with fibromyalgia, the search for relief is often a years-long journey through physical therapy, medications, and lifestyle adjustments. Recently, some patients have turned to hyperbaric oxygen therapy (HBOT), reporting reductions in pain sensitivity and improved energy levels after sessions in pressurized chambers. The question is whether these improvements reflect a genuine physiological effect—or the placebo response that so often complicates chronic pain research.
What the Studies Actually Show
Research into HBOT for fibromyalgia remains in early stages, consisting primarily of small cohort studies and case series rather than the large randomized controlled trials that establish standard medical care. A 2022 observational study from researchers in Israel followed 30 women with fibromyalgia through 40 HBOT sessions, reporting statistically significant reductions in pain scores and tender point counts compared to baseline. The proposed mechanism centers on neuroinflammation: fibromyalgia involves abnormal pain processing in the central nervous system, and HBOT’s ability to reduce inflammatory cytokines while improving tissue oxygenation might, in theory, modulate these hypersensitized pathways.
More recently, a 2026 prospective cohort study from Charité–Universitätsmedizin Berlin examined HBOT in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), a condition that shares significant symptom overlap with fibromyalgia. Using functional MRI, researchers documented changes in thalamic connectivity following HBOT protocols, correlating these imaging findings with patient-reported improvements in functional capacity. While not directly studying fibromyalgia, the research suggests HBOT may influence central pain processing mechanisms relevant to multiple chronic pain conditions.
The evidence, however, comes with substantial caveats. These studies lack control groups receiving sham treatment, making it impossible to distinguish genuine HBOT effects from the natural fluctuation of fibromyalgia symptoms or placebo response. The sample sizes are small—often fewer than 50 participants—and the long-term durability of any benefits remains unstudied. No major medical society has issued clinical guidelines supporting HBOT for fibromyalgia based on current evidence.
The FDA’s Position: Not Cleared for Fibromyalgia
The U.S. Food and Drug Administration has not cleared hyperbaric oxygen therapy for fibromyalgia, chronic fatigue syndrome, or any related chronic pain conditions. This places these uses squarely in the off-label category—legal for physicians to prescribe, but not validated through the FDA’s rigorous review process for safety and efficacy.
The FDA’s cleared indications for HBOT remain focused on specific, serious medical conditions: decompression sickness, carbon monoxide poisoning, arterial gas embolism, certain non-healing diabetic wounds, late radiation tissue injury, gas gangrene, severe anemia when transfusion isn’t possible, compromised skin grafts and flaps, crush injuries, thermal burns, and idiopathic sudden sensorineural hearing loss. Fibromyalgia does not appear on this list, nor does the FDA recognize it as an emerging indication with sufficient evidence for consideration.
In its August 2025 safety communication, the FDA specifically warned against using HBOT for unproven indications, noting that patients seeking treatment for conditions like autism, Alzheimer’s disease, stroke, multiple sclerosis, and chronic pain may be exposed to risks without demonstrated benefits. The agency emphasized that HBOT devices are Class II medical devices requiring proper medical supervision—and that the fire and oxygen toxicity risks associated with these devices are only justified when treating conditions with established clinical benefit.
Why the Caution Matters
HBOT is not a benign wellness treatment. The therapy involves breathing 100% oxygen at pressures typically 1.5 to 3 times normal atmospheric pressure, creating real physiological risks that require medical monitoring. Barotrauma—pressure-related injury to the ears, sinuses, or lungs—can occur during pressurization or decompression. Oxygen toxicity, though rare at therapeutic doses, can cause seizures. The hyper-oxygenated environment creates fire hazards that have resulted in serious injuries and deaths when safety protocols are not strictly followed.
For fibromyalgia patients specifically, the financial cost adds another layer of concern. Without FDA clearance, insurance companies universally deny coverage for HBOT in this context. A typical course of 40 sessions—the protocol used in most positive studies—can cost $10,000 to $20,000 or more when paid out-of-pocket. Patients spending these sums on unproven therapy may have fewer resources available for evidence-based treatments with demonstrated benefit.
The Research Frontier
Despite regulatory caution, legitimate scientific interest in HBOT for chronic pain continues. The underlying hypothesis—that HBOT might reduce central sensitization through anti-inflammatory and neuroplastic mechanisms—is biologically plausible and supported by preliminary imaging studies. Several research groups are reportedly designing randomized controlled trials with sham control conditions, which would provide the quality of evidence currently missing from the literature.
The Undersea and Hyperbaric Medical Society, the primary professional organization for HBOT practitioners, maintains a position of neutrality on off-label uses while emphasizing that any HBOT should be delivered in accredited facilities with appropriate medical oversight. The society’s 15 approved indications do not include fibromyalgia, and UHMS has not issued guidance suggesting this is likely to change based on current evidence.
What Patients Should Know
For fibromyalgia patients considering HBOT, the decision requires careful weighing of unproven potential benefits against documented risks and substantial costs. The therapy should not replace evidence-based treatments—exercise programs, cognitive behavioral therapy, FDA-approved medications like duloxetine or pregabalin, and multidisciplinary pain management approaches with established efficacy.
Patients who do pursue HBOT should seek treatment only at UHMS-accredited facilities with board-certified hyperbaric physicians, not wellness centers or spas offering “mild hyperbaric” treatments in soft chambers that cannot achieve the pressures used in clinical studies. They should understand that any benefits are uncertain, that insurance will not cover the cost, and that the FDA has specifically warned against this use.
The story of HBOT in fibromyalgia illustrates a broader pattern in chronic pain medicine: desperate patients, limited treatment options, and therapies that show promise in early studies but fail to hold up under rigorous testing. Whether HBOT will prove different remains an open question—one that only well-designed clinical trials can answer.
HBOToday Editorial provides evidence-based reporting on hyperbaric medicine. This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making treatment decisions.